ReviewFrontiers in pharmacology2026
Oxidative stress driven airway mesenchymal reprogramming in asthma: mechanistic insights and evidence from botanical drug formulations.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma-associated airway mesenchymal reprogramming refers to a dynamic pathological process characterized by persistent pathological alterations in phenotype, function, and intercellular interactions of airway mesenchymal cells under asthmatic conditions, which actively drive airway structural changes, airway narrowing, and impaired lung function. It is considered one of the key pathological mechanisms driving the chronic progression of asthma and contributing to persistent airflow limitation. Oxidative stress, as a central pathogenic factor, drives asthma-associated airway mesenchymal reprogramming through multiple mechanisms, including promoting inflammation, inducing epithelial-to-mesenchymal transition (EMT), exacerbating airway smooth muscle dysfunction, and impairing endogenous antioxidant defense systems. Increasing evidence suggests that this reprogramming may initiate at early stages of asthma, highlighting its potential relevance as an early pathogenic indicator. Although standard therapies such as inhaled corticosteroids and β
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.